FDA-Approved for Visceral Fat
Tesamorelin
Precision metabolic reset
Starting at $400
The only FDA-approved GHRH analogue shown to specifically reduce dangerous visceral adipose tissue. Originally developed for HIV-associated lipodystrophy, now prescribed for metabolic optimization. Tesamorelin targets the deep abdominal fat that drives insulin resistance, inflammation, and cardiovascular risk.
Targeted visceral fat mobilization
Unlike off-label peptide use, Tesamorelin has a validated safety profile, established dosing protocols, and regulatory oversight based on rigorous clinical trials published in NEJM (2010) and Lancet (2010).
GH Rhythm
Pulsatile GH Restoration
Tesamorelin stimulates your pituitary to release growth hormone in natural pulses, restoring the GH rhythm that declines with age and metabolic dysfunction. This normalized GH secretion drives the metabolic benefits.
Result: Restored GH levels without exogenous hormone replacement
Fat Specialist
Visceral Fat Mobilization
The restored GH specifically targets visceral adipose tissue — the metabolically dangerous fat surrounding your organs. Visceral fat is more responsive to GH-mediated lipolysis than subcutaneous fat.
Result: Clinically proven 15.2% reduction in visceral adipose tissue
Systemic Benefits
Metabolic Optimization
By reducing visceral fat, Tesamorelin improves glucose metabolism, insulin sensitivity, and lipid profiles. Visceral fat produces inflammatory cytokines and hormones that drive metabolic dysfunction — removing it addresses the root cause.
Result: Improved glucose tolerance, triglycerides, and HDL cholesterol
Clinical Benefits
What you can expect from Tesamorelin therapy
Visceral Fat Reduction
Clinically proven to reduce dangerous belly fat by 15.2% at 26 weeks, with sustained reductions at one year.
Improved Insulin Sensitivity
Enhances glucose tolerance in patients with impaired fasting glucose, addressing metabolic dysfunction at its source.
Favorable Lipid Profile
Reduces triglycerides and increases HDL cholesterol, improving cardiovascular risk markers.
Lean Mass Preservation
Maintains lean muscle mass during visceral fat loss, preventing the muscle wasting often seen with caloric restriction.
Cardiovascular Protection
Reduces visceral fat that drives inflammation, insulin resistance, and cardiovascular disease risk.
Metabolic Resilience
Addresses the root metabolic dysfunction driving weight gain, making it easier to maintain results long-term.
The Process
What to expect & when
Realistic timeline for Tesamorelin results
Weeks 1–4
Metabolic Adaptation
Your body begins responding to restored GH pulses. Energy and recovery may improve as metabolic function optimizes.
Weeks 8–12
Early VAT Reduction
Initial visceral fat mobilization begins. Waist circumference may start to decrease, though changes are subtle.
Weeks 12–26
Significant VAT Loss
Measurable visceral fat reduction on imaging. Waist circumference visibly decreases. Metabolic markers begin improving.
Week 26
Peak VAT Reduction
Clinical trials showed 15.2% visceral adipose tissue reduction at this timepoint — maximum benefit for most patients.
6–12 Months
Sustained Results
Maintained visceral fat reduction with continued use. Metabolic improvements (glucose, lipids) fully manifest and stabilize.
Common questions
Everything you need to know about Tesamorelin therapy
Transparent Pricing
Consultation Fees
Physician-guided care with complete pricing clarity.
Generic Consultation
Includes Any & All Services
First Visit
$400
Follow-Up
$150
- Complete health assessment
- All service areas covered
- Personalized treatment plan
- Prescription if appropriate
Specialized Consultation
Skin, Hair, Wellness, Labs, Galleri
First Visit
$300
Follow-Up
$150
- Focused specialty review
- Lab analysis included
- Targeted treatment approach
- Follow-up protocol
Peptide Consultation
Weight loss & metabolic therapies
First Visit
$50
Follow-Up
$30
- Metabolic assessment
- GLP-1 or peptide evaluation
- Dosing strategy
- Prescription included